Cargando…
Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS)
BACKGROUND: Recent evidence suggests that there may be a bidirectional, physiological link between hypogonadism and metabolic syndrome (MetS), and testosterone replacement therapy (TRT) has been shown to improve some symptoms of MetS in small patient populations. We examined the effect of 12 months...
Autores principales: | Bhattacharya, Rajib K, Khera, Mohit, Blick, Gary, Kushner, Harvey, Nguyen, Dat, Miner, Martin M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217857/ https://www.ncbi.nlm.nih.gov/pubmed/22044661 http://dx.doi.org/10.1186/1472-6823-11-18 |
Ejemplares similares
-
Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS)
por: Bhattacharya, Rajib K, et al.
Publicado: (2012) -
Testosterone replacement in male hypogonadism
por: Kalra, Sanjay, et al.
Publicado: (2010) -
A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism
por: DelConte, Anthony, et al.
Publicado: (2022) -
SAT-038 Ambulatory Blood Pressure Increases in Hypogonadal Men Who Develop Increases in Hematocrit on Oral Testosterone Undecanoate
por: Dobs, Adrian Sandra, et al.
Publicado: (2020) -
Testosterone Replacement Therapy and Bone Mineral Density in Men with Hypogonadism
por: Kim, Se Hwa
Publicado: (2014)